Zentalis Pharmaceuticals Inc. (ZNTL) carries a Roarable Rating of D- (Sell) with 39/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.96 (-1.51% 1D, market cap $188.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ZNTL ranks #554 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZNTL carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, WHWK (Whitehawk Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $188.1M) and ADCT (ADC Therapeutics SA) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $190.2M). Among the 5-stock peer group, ZNTL leads on earnings multiple (N/A) while SION leads on capital efficiency (-28.3% ROIC).
Per ZNTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001725160), Zentalis Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$137.1M in net income, and -$125.2M in free cash flow against $289.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
FRED Regime × Technicals: 13% of 52W Range • RSI-14 at 31.1 (OVERSOLD (<32))
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While ZNTL currently carries a cautious 39/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.95) and Max Pain ($2.06) forces dealer call-delta covering toward $7.30.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Zentalis Pharmaceuticals Inc. (ZNTL) slipped -1.51% to $1.96, trading at 13% of its 52-week range ($1.21 – $6.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
Median overall survival of 15.9 months in Cyclin E1-positive PROC, with 1–5 prior lines of therapy; safety profile in DENALI Part 1b was consistent with prior reportingMedian relative dose intensity was 84.6%, confirming
Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ZNTL today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ZNTL. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Zentalis Pharmaceuticals Inc. (ZNTL) ranks #554 by composite RQD confidence (39/100, grade D-) and #585 by equity capitalization ($188.4M). Within this direct 5-issuer industry benchmark cohort, ZNTL leads on earnings valuation at N/A trailing P/E, while SION leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. YARW currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with ZNTL at 39/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ZNTL
ACTIVE
Zentalis Pharmaceuticals Inc. | D- | 39/100 | — | — | -35.0% | -1.51% | $188.4M | Benchmark Subject |
| WHWK Whitehawk Therapeutics Inc. | E | 28/100 | — | 89.4% | -35.0% | -1.82% | $188.1M | /whwk-vs-zntl → |
| ADCT ADC Therapeutics SA | E | 33/100 | — | 92.9% | -35.0% | +2.69% | $190.2M | /adct-vs-zntl → |
| YARW Yarrow Bioscience Inc. | D- | 41/100 | — | — | -35.0% | -0.50% | $186.1M | /yarw-vs-zntl → |
| SION Sionna Therapeutics Inc. | D- | 38/100 | — | — | -28.3% | -3.25% | $180.8M | /sion-vs-zntl → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zentalis Pharmaceuticals Inc. (ZNTL) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $67.4M ) , GAAP net income of -$137.1M, operating cash flow of -$125.2M, and free cash flow of -$125.2M (+26.8% YoY). On the balance sheet, ZNTL closed FY2025 with $289.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$137.1M | -$125.2M | -$125.2M | $289.0M | — |
| FY2024 (FY) | 2024-12-31 | $67.4M | -$165.9M | -$170.9M | -$171.1M | $430.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$292.3M | -$207.8M | -$207.8M | — | — |
As of 2026-11-02, Zentalis Pharmaceuticals Inc. (NASDAQ: ZNTL) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 39/100 at a spot price of $1.96 (-1.51% 1D, market cap $188.4M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ZNTL ranks #554 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZNTL carries a Roarable D- (39/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, WHWK (Whitehawk Therapeutics Inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $188.1M) and ADCT (ADC Therapeutics SA) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $190.2M). Among the 5-stock peer group, ZNTL leads on earnings multiple (N/A) while SION leads on capital efficiency (-28.3% ROIC).
Per ZNTL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001725160), Zentalis Pharmaceuticals Inc. generated $0 in revenue (-100.0% YoY), -$137.1M in net income, and -$125.2M in free cash flow against $289.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ZNTL last traded at $1.96 (-1.51% on volume of 1,332,601 shares), positioning the stock -33.56% below its 50-day simple moving average ($2.95) and -43.19% below its 200-day simple moving average ($3.45). Across its 52-week range of $1.21 to $6.95, ZNTL sits at the 13.1% percentile with a 14-day RSI of 31.1 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.72 to $2.20).
Why ZNTL Stock slipped -1.51% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, ZNTL scores 39 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow."
For a prospective investor evaluating the stock today, the rating frames ZNTL as a high-risk setup: the upside case rests on pipeline or catalyst outcomes outside the reported financials, while the downside case rests on continued cash burn and weak flow signals. Valuation tradeoffs are difficult to assess because earnings-based multiples are not available in the source data.
Zentalis Pharmaceuticals Inc. (ZNTL) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.2B. Per the SEC financials, FY 2024 revenue was $67.4M, while FY 2025 and FY 2023 revenue were $0.0M. Not available in source data for detailed product descriptions, customer segments, or revenue model.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-152.8M | $-137.1M | N/A | $-125.2M | $36.0M | N/A |
| FY 2024 | $67.4M | $-191.2M | $-165.9M | N/A | $-171.1M | $33.9M | N/A |
| FY 2023 | $0.0M | $-299.5M | $-292.3M | N/A | $-207.8M | N/A | N/A |
Per the SEC financials, the company reported operating and net losses across all three periods, and margins per the market data are 0% for gross, operating, and net. Per the Roarable RQD rating, ROIC is -35%. Per the Roarable RQD rating, Altman Z-Score is 2.5, Piotroski F-Score is 3/9, and Debt/Equity is 0.5. The balance sheet posture is weak on flow metrics despite the moderate Altman reading.
Per the recent news and catalysts section:
Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no butterfly links and no proprietary signals.
Real-time company headlines, analyst actions, and sector developments for Zentalis Pharmaceuticals Inc. (ZNTL) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
ad-hoc-news.de report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Zentalis Pharmaceuticals Inc. (ZNTL) market action, institutional positioning, and fundamental catalysts.
Welcome to the ZNTL (Zentalis Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 39/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on ZNTL, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Zentalis Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on ZNTL, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.96 (52-wk range $1.21 - $6.95), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).